Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to ...
Investing21h
US Dollar Index (DXY)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...